Shanghai Kaibao Pharmaceutical (300039) — Cash Flow Reinvestment Rate
Shanghai Kaibao Pharmaceutical (300039) has a Cash Flow Reinvestment Rate of 0.02x as of September 2025, reinvesting CN¥3.37 Million (capex CN¥3.37 Million ) from operating cash flow of CN¥190.98 Million. See Shanghai Kaibao Pharmaceutical (300039) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Shanghai Kaibao Pharmaceutical Cash Flow Reinvestment Rate (2006–2025)
Historical reinvestment intensity for Shanghai Kaibao Pharmaceutical across 20 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Shanghai Kaibao Pharmaceutical.
Annual Cash Flow Reinvestment Rate for Shanghai Kaibao Pharmaceutical (2006–2025)
Year-by-year capital reinvestment analysis for Shanghai Kaibao Pharmaceutical. See financial agility of Shanghai Kaibao Pharmaceutical to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 1.56x | CN¥360.37 Million | CN¥230.74 Million | CN¥27.04 Million | ▲ +199.5% |
| 2024 | 0.52x | CN¥145.48 Million | CN¥278.95 Million | CN¥140.52 Million | ▼ -12.4% |
| 2023 | 0.60x | CN¥227.71 Million | CN¥382.66 Million | CN¥29.08 Million | ▼ -29.3% |
| 2022 | 0.84x | CN¥316.99 Million | CN¥376.42 Million | CN¥31.62 Million | ▲ +46.5% |
| 2021 | 0.57x | CN¥72.48 Million | CN¥126.08 Million | CN¥42.55 Million | ▲ +73.0% |
| 2020 | 0.33x | CN¥83.28 Million | CN¥250.65 Million | CN¥13.94 Million | ▼ -82.2% |
| 2019 | 1.86x | CN¥622.91 Million | CN¥334.09 Million | CN¥15.46 Million | ▲ +155.3% |
| 2018 | 0.73x | CN¥191.63 Million | CN¥262.36 Million | CN¥26.07 Million | ▼ -25.3% |
| 2017 | 0.98x | CN¥240.28 Million | CN¥245.76 Million | CN¥49.24 Million | ▼ -29.5% |
| 2016 | 1.39x | CN¥436.47 Million | CN¥314.88 Million | CN¥27.03 Million | ▲ +330.4% |
| 2015 | 0.32x | CN¥105.34 Million | CN¥327.08 Million | CN¥50.40 Million | ▲ +32.3% |
| 2014 | 0.24x | CN¥68.74 Million | CN¥282.38 Million | CN¥68.74 Million | ▼ -44.4% |
| 2013 | 0.44x | CN¥118.28 Million | CN¥270.23 Million | CN¥118.28 Million | ▲ +104.0% |
| 2012 | 0.21x | CN¥52.21 Million | CN¥243.32 Million | CN¥52.21 Million | ▼ -69.4% |
| 2011 | 0.70x | CN¥68.85 Million | CN¥98.31 Million | CN¥68.85 Million | ▼ -72.8% |
| 2010 | 2.58x | CN¥51.01 Million | CN¥19.79 Million | CN¥51.01 Million | ▲ +8.1% |
| 2009 | 2.38x | CN¥125.70 Million | CN¥52.74 Million | CN¥125.70 Million | ▲ +294.9% |
| 2008 | 0.60x | CN¥11.28 Million | CN¥18.70 Million | CN¥11.28 Million | ▲ +204.1% |
| 2007 | 0.20x | CN¥4.62 Million | CN¥23.27 Million | CN¥4.62 Million | ▼ -66.7% |
| 2006 | 0.60x | CN¥11.74 Million | CN¥19.70 Million | CN¥11.74 Million | — |